relapse in dlbcl - addressing the unmet need with brentuximab vedotin
Published 7 years ago • 348 plays • Length 2:25Download video MP4
Download video MP3
Similar videos
-
3:04
treatment options for patients with lbcl who relapse or are refractory to initial treatment
-
3:10
the potential for early identification of relapse in dlbcl using serial ctdna sampling
-
1:16
unmet needs in second-line dlbcl and challenges in this space
-
3:35
outcomes of patients with dlbcl who relapse early following r-ice chemoimmunotherapy
-
8:23
hodgkin rash/itch
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
4:11
chronic myeloid leukemia: a patient's journey
-
1:59
understanding the biology behind aml relapse
-
3:18
granulocytes & t-cells as biomarkers for relapse in cml following discontinuation of tkis
-
1:39
retreatment with a btki plus venetoclax after relapse is effective in cll: insights from captivate
-
0:43
phase i study of rapcabtagene autoleucel in patients with r/r dlbcl
-
1:23
next steps for hodgkin lymphoma - combining brentuximab vedotin with checkpoint inhibitors
-
2:29
evaluating the combination of nivolumab and lenalidomide in relapsed hl and lbcl
-
3:16
developing patient-specific mrd markers for predicting and preventing mds relapse post-sct
-
1:26
unmet needs in hodgkin lymphoma
-
0:44
autologous transplantation in dlbcl and unmet needs